Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Genflow Biosciences PLC Announces Issue of Equity | 196 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
Do | Genflow Biosciences - Issue of Equity - Correction | 2 | RNS | ||
GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
Do | SMALL-CAP WINNERS & LOSERS: Argo Blockchain up; Genflow issues shares | 12 | Alliance News | ||
Do | Genflow Biosciences - Issue of Equity | 2 | RNS | ||
Di | Genflow Biosciences PLC Announces Half-Year Report | 332 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.Chairman's StatementIt... ► Artikel lesen | |
Di | Genflow Biosciences - Half-year Report | 1 | RNS | ||
19.09. | Genflow Biosciences PLC Announces Holding(s) in Company | 208 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
19.09. | Genflow files patent examination request in China for NASH treatment | 4 | Investing.com | ||
19.09. | Genflow treibt Patent für NASH-Behandlung in China voran | 2 | Investing.com Deutsch | ||
19.09. | Genflow Biosciences PLC: Genflow Strengthens IP Portfolio | 159 | ACCESS Newswire | Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH LONDON, UK / ACCESS Newswire / September 19, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF)... ► Artikel lesen | |
19.09. | Genflow Biosciences - Genflow Strengthens IP Portfolio | 1 | RNS | ||
15.09. | Genflow schließt Vertraulichkeitsabkommen mit führenden Tiergesundheitsunternehmen | 2 | Investing.com Deutsch | ||
15.09. | Genflow signs confidentiality deals with animal health companies | 1 | Investing.com | ||
15.09. | Genflow Biosciences PLC: Genflow Signs CDAs with Animal Health Companies | 230 | ACCESS Newswire | Genflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform LONDON, UK / ACCESS Newswire / September 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow"... ► Artikel lesen | |
15.09. | Genflow Biosciences - Genflow Signs CDAs with Animal Health Companies | - | RNS | ||
18.08. | Baidu.Inc: Baidu Wenku and Netdisk Launch GenFlow 2.0, Deploying Over 100 AI Agents Simultaneously | 391 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- Baidu Wenku and Netdisk, Baidu's AI-powered productivity apps, have introduced GenFlow 2.0, a general AI agent featuring more than 100 parallel agents... ► Artikel lesen | |
18.08. | Genflow: Gentherapie-Studie zur Langlebigkeit bei Hunden zeigt keine Nebenwirkungen | 7 | Investing.com Deutsch | ||
18.08. | Genflow reports no adverse effects in dog longevity gene therapy trial | 2 | Investing.com | ||
18.08. | Genflow Biosciences PLC Announces Company Update on Dog Trials | 195 | ACCESS Newswire | Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported LONDON, UK / ACCESS Newswire / August 18, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF)... ► Artikel lesen | |
18.08. | Genflow Biosciences - Company Update on Dog Trials | 1 | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
EVOTEC | 6,744 | +2,00 % | Rheinmetall Aktie: Große Chance? - ABO Energy, Evotec, Funkwerk, MPC Capital und Redcare Pharmacy im Marktbericht Börse Frankfur | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
LENZ THERAPEUTICS | 48,740 | +0,87 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 65,18 | +10,89 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 47,010 | +6,41 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |